Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

被引：2

作者：

Strati, Paolo ^{[1
]}

Champion, Rebecca ^{[2
]}

Coleman, Morton ^{[3
]}

Smith, Sonali M. ^{[4
]}

Venugopal, Parameswaran ^{[5
]}

Martin, Peter ^{[6
]}

Wood, Andrew ^{[7
]}

Miller, Kara ^{[8
]}

Christian, Beth ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Norton Canc Inst, Louisville, KY USA

[3] Weill Cornell Med, Clin Res Alliance, New York, NY USA

[4] Univ Chicago, Med Ctr, Chicago, IL USA

[5] Rush Univ, Med Ctr, Chicago, IL USA

[6] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[7] AstraZeneca, Cambridge, England

[8] AstraZeneca, South San Francisco, CA USA

[9] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 06期

关键词：

B-cell lymphoma; Bruton tyrosine kinase; non-Hodgkin lymphoma; TYROSINE KINASE INHIBITOR; B-CELLS; IBRUTINIB; ACP-196;

D O I：

10.1111/bjh.19787

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.

引用

页码：2248 / 2253

页数：6

共 50 条

[1] Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)
Strati, Paolo
Agajanian, Richy
Lossos, Izidore S.
Coleman, Morton
Kridel, Robert
Wood, Andrew
Lesley, Robin
Wun, Chuan-Chuan
Stephens, Deborah M.
BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (03) : 887 - 898
[2] A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Strati, Paolo
Coleman, Morton
Champion, Rebecca
Ma, Shuo
Patti, Caterina
Levy, Moshe Y.
Lossos, Izidore S.
Geethakumari, Praveen Ramakrishnan
Lam, Selay
Calvo, Roser
Higgins, Kara
Budde, Lihua E.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (01) : 76 - 85
[3] A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma
Paikaray, Sushant Kumar
Gogia, Ajay
Kumar, Lalit
Sharma, Atul
Biswas, Ahit Agni
Vishnubhatla, Sreeniwas
Mallick, Soumya
INDIAN JOURNAL OF CANCER, 2023, 60 (04) : 501 - 504
[4] A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
Carlo-Stella, Carmelo
Zinzani, Pier Luigi
Sureda, Anna
Araujo, Luis
Casasnovas, Olivier
Carpio, Cecilia
Yeh, Su-Peng
Bouabdallah, Krimo
Cartron, Guillaume
Kim, Won Seog
Cordoba, Raul
Koh, Youngil
Re, Alessandro
Alves, Daniela
Chamuleau, Martine
Le Gouill, Steven
Lopez-Guillermo, Armando
Moreira, Ilidia
van der Poel, Marjolein W. M.
Abbadessa, Giovanni
Meng, Robin
Ji, Ran
Lepine, Lucie
Saleem, Rao
Ribrag, Vincent
HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 108 - 119
[5] Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Gopal, Ajay K.
Schuster, Stephen J.
Fowler, Nathan H.
Trotman, Judith
Hess, Georg
Hou, Jing-Zhou
Yacoub, Abdulraheem
Lill, Michael
Martin, Peter
Vitolo, Umberto
Spencer, Andrew
Radford, John
Jurczak, Wojciech
Morton, James
Caballero, Dolores
Deshpande, Sanjay
Gartenberg, Gary J.
Wang, Shean-Sheng
Damle, Rajendra N.
Schaffer, Michael
Balasubramanian, Sriram
Vermeulen, Jessica
Cheson, Bruce D.
Salles, Gilles
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2405 - +
[6] Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
Lansigan, Frederick
Costa, Cristiana A.
Zaki, Bassem I.
Yen, Stephanie P.
Winer, Eric S.
Ryan, Helen
Findley, Darcie
Metzler, Sara R.
Shaw, Lynn
Toaso, Bonnie
MacKenzie, Todd A.
Chen, Youdinghuan
Beaven, Anne W.
CLINICAL CANCER RESEARCH, 2019, 25 (20) : 6073 - 6079
[7] A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
Izutsu, Koji
Kato, Hisashi
Sekiguchi, Naohiro
Fujisaki, Tomoaki
Kawakita, Toshiro
Obara, Naoshi
Matsue, Kosei
Nishimoto, Mitsutaka
Hatayama, Tomoyoshi
Inagaki, Mitsuo
Fujikawa, Ei
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 80 - 90
[8] Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial
Becnel, Melody R.
Nastoupil, Loretta J.
Samaniego, Felipe
Davis, Richard E.
You, M. J.
Green, Michael
Hagemeister, Fredrick B.
Fanale, Michelle A.
Fayad, Luis E.
Westin, Jason R.
Wang, Michael
Oki, Yasuhiro
Forbes, Sheryl G.
Feng, Lei
Neelapu, Sattva S.
Fowler, Nathan H.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 874 - 882
[9] An open-label trial of rituximab therapy in pulmonary alveolar proteinosis
Kavuru, M. S.
Malur, A.
Marshall, I.
Barna, B. P.
Meziane, M.
Huizar, I.
Dalrymple, H.
Karnekar, R.
Thomassen, M. J.
EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (06) : 1361 - 1367
[10] Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
Huang, Xiaojun
Qiu, Lugui
Jin, Jie
Zhou, Daobin
Chen, Xiequn
Hou, Ming
Hu, Jianda
Hu, Yu
Ke, Xiaoyan
Li, Junmin
Liang, Yingmin
Liu, Ting
Lv, Yue
Ren, Hanyun
Sun, Aining
Wang, Jianmin
Zhao, Chunting
Salman, Mariya
Sun, Steven
Howes, Angela
Wang, Jingzhao
Wu, Peng
Li, Jianyong
CANCER MEDICINE, 2018, 7 (04): : 1043 - 1055

← 1 2 3 4 5 →